Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2025-12-25 @ 1:33 AM
NCT ID: NCT00269594
Eligibility Criteria: Inclusion Criteria: * men and women age 18-65 * current diagnosis of neurotic excoriation Exclusion Criteria: * unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination * history of seizures * myocardial infarction within 6 months * current pregnancy or lactation, or inadequate contraception in women of childbearing potential * a need for medication other than Lamictal with possible psychotropic effects or unfavorable interactions with Lamictal * clinically significant suicidality * lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder * current or recent (past 3 months) DSM-IV substance abuse or dependence * illegal substance use within 2 weeks of study initiation * initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline * previous treatment with Lamictal * treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline * current treatment with an anti-epileptic medication and * patients who have previously been diagnosed with a medical condition that cause skin itchiness (e.g. liver, kidney, and blood diseases, etopic allergies)
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT00269594
Study Brief:
Protocol Section: NCT00269594